More
A study led by researchers from the International Agency for Research on Cancer (IARC) and partners is comparing the effectiveness of a single dose of human papillomavirus (HPV) vaccine versus three or two doses to protect against persistent HPV infection, which is the necessary cause of cervical cancer. Early findings from this multicentre trial in India indicate that a single dose of quadrivalent HPV vaccine generates robust antibody response and provides similar protection against HPV16 and HPV18 persistent infections as immunization based on the three- or two-dose vaccine schedules.
Sankaranarayanan R, Joshi S, Muwonge R, Esmy PO, Basu P, Prabhu P, et al.; Indian HPV Vaccine Study Group
Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study
Vaccine. Published online 15 March 2018;
http://dx.doi.org/10.1016/j.vaccine.2018.02.087
